↓ Skip to main content

Artemisinin derivatives for treating uncomplicated malaria

Overview of attention for article published in Cochrane database of systematic reviews, April 1999
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs
1 blog
policy
1 policy source

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Artemisinin derivatives for treating uncomplicated malaria
Published in
Cochrane database of systematic reviews, April 1999
DOI 10.1002/14651858.cd000256
Pubmed ID
Authors

Heather McIntosh, Piero Olliaro

Abstract

Artemisinin derivatives are a relatively new group of drugs with antimalarial properties. As resistance to other antimalarial drugs continues to increase, artemisinin drugs may be useful alternatives. The objective of this review was to assess the effects of artemisinin drugs for treating uncomplicated falciparum malaria. We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline, Embase, Science Citation Index, Lilacs, African Index Medicus; conference abstracts and reference lists of relevant articles. We contacted organisations, researchers in the field and drug companies. Randomised and quasi-randomised trials of artemisinin derivatives, alone or in combination with other antimalarials, compared with standard antimalarial treatments, in adults or children with uncomplicated falciparum malaria. Only trials where treatment was given by mouth or suppository were included. Comparisons between different artemisinin derivatives and treatment regimens were also included. Eligibility and trial quality were assessed and data were extracted independently by the two reviewers. Forty-one trials involving over 5000 patients were included. Variation in study design and quality made synthesis of the data problematic. Allocation concealment was adequate in only two trials. Most data were from areas of multidrug resistant falciparum malaria in South East Asia. Compared with standard antimalarial treatments, artemisinin drugs showed fast parasite clearance and high cure rates at follow-up, provided the duration of treatment with artemisinin drugs was adequate. Combination with mefloquine improved sustained parasite clearance and was effective in multidrug resistant areas. When doses were adequate, the combination shortened the duration of treatment. We found no evidence that artemisinin drugs are more harmful than standard treatment drugs over a typical trial period of 28 days. The evidence suggests that artemisinin drugs are effective and safe for treating uncomplicated malaria. There is no evidence from randomised trials that one artemisinin derivative is better than the others. In areas where there is mefloquine resistance, combination therapy with an artemisinin derivative appears to improve sustained parasite clearance compared with either drug alone.

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 2 3%
United Kingdom 2 3%
Germany 1 1%
Unknown 74 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 16%
Researcher 12 15%
Student > Master 11 14%
Unspecified 9 11%
Other 8 10%
Other 26 33%
Readers by discipline Count As %
Medicine and Dentistry 29 37%
Unspecified 11 14%
Agricultural and Biological Sciences 11 14%
Nursing and Health Professions 7 9%
Biochemistry, Genetics and Molecular Biology 5 6%
Other 16 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 November 2015.
All research outputs
#1,752,574
of 12,527,093 outputs
Outputs from Cochrane database of systematic reviews
#3,881
of 8,923 outputs
Outputs of similar age
#47,252
of 275,545 outputs
Outputs of similar age from Cochrane database of systematic reviews
#137
of 228 outputs
Altmetric has tracked 12,527,093 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,545 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 228 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.